Meiji Announces Board Approval for Capital Increase in Korean Subsidiary Alvogen Korea Holdings Ltd.

1. Name and nature of the subject matter (for preferred shares, specify issuance terms such as dividend rate): Ordinary shares of Alvogen Korea Holdings Ltd., a 100%-owned subsidiary of the Company in Korea

2. Date of occurrence: June 26, 2026 ~ June 26, 2026

3. Board approval date: June 26, 2026 (R.O.C. Year 115)

4. Other approval dates: Not applicable

5. Transaction quantity, unit price, and total transaction amount: Number of units: 154,779 shares Unit price: USD 85.57 Total transaction amount: USD 13,245,033.11

6. Counterparty and its relationship with the company (if the counterparty is a natural person and not a related party of the company, name disclosure may be omitted): Alvogen Korea Holdings Ltd. is a 100%-owned subsidiary of the Company.

7. If the counterparty is a related party, state the reason for selecting such party, previous transferor, relationships among previous transferor, company, and counterparty, transfer date, and transfer amount: Not applicable

8. If the ownership of the subject matter was held by a related party of the company within the past five years, state the date and price of acquisition and disposal, and the relationship with the company at the time: Not applicable

9. Matters related to the disposal of receivables (including types of collateral attached to disposed receivables; if receivables from related parties are involved, state the name of the related party and the book value of receivables disposed): Not applicable

10. Gain (or loss) from disposal (not applicable for acquisition of securities) (if previously deferred, explain recognition status): Not applicable

11. Delivery or payment terms (including payment periods and amounts), contractual restrictions, and other important agreements: Not applicable

12. Decision-making method for this transaction, reference basis for price determination, and decision-making unit: The transaction price was referenced from the reasonableness opinion issued by the accountant and executed upon approval by the Company's board of directors.

13. Net asset value per share of the securities-issuing company: NT$2,735.18

14. Cumulative holdings (including this transaction) of the securities involved, including quantity, amount, ownership percentage, and any restrictions on rights (e.g., pledge status): Cumulative holdings: 1,611,378 shares Cumulative amount: NT$5,277,342,848 Ownership percentage: 100% Rights restriction status: None

15. Proportion of securities investments (including this transaction) under Article 3 of the 'Asset Acquisition and Disposition Rules for Publicly Issued Companies' to the company's total assets and equity attributable to owners of the parent in the most recent financial statements, and the amount of working capital in the most recent financial statements: Percentage of total assets: 51.63% Percentage of equity attributable to owners of the parent: 110.08% Working capital amount: NT$6,168,243,683

16. Broker and brokerage fees: Not applicable

17. Specific purpose or use of the acquisition or disposal of securities: To enhance the efficiency of operational fund utilization

18. Dissenting directors' opinions on this transaction: None

19. Whether this transaction is a related-party transaction: Yes

20. Date of auditor's approval or audit committee's consent: June 25, 2026 (R.O.C. Year 115)

21. Whether the accountant issued a non-reasonable opinion: No

22. Name of accounting firm: Yang Chih & Associates Certified Public Accountants

23. Name of accountant: Hu Hsiang-Ning

24. Accountant's license number: Taichung City CPA Certificate No. 0191

25. Whether this involves a change in business model: No

26. Explanation of business model change: Not applicable

27. Transaction history with the counterparty in the past year and expected in the next year: Not applicable

28. Source of funds: Not applicable

29. Previous date of material information disclosure regarding the same event: Not applicable

30. Other explanatory matters: 1. The total capital increase amount is converted from the Company's receivable claims against Alvogen Korea Holdings Ltd. into capital contribution. 2. The actual number of shares issued in the capital increase shall be based on the conversion number as of the capital increase benchmark date. 3. The transaction amount is calculated based on the Taiwan Bank exchange rate quoted on June 22, 2026 (R.O.C. Year 115), with 1 USD = NT$31.64.